Organon has reported a cumulative six-year Pearl Index of 0.93 and an estimated pregnancy rate of 3.9% for the hormone-free MIUDELLA intrauterine system. The findings support an FDA application to extend its approved use from three to six years, with a decision expected in the second quarter of 2027.
AbCellera will report Phase 2 ABCL635 data on Aug. 10, testing whether a long-acting NK3 antibody can reduce menopause hot flashes.
Discover how Vilo Signal OS plans to turn smart ring data into proactive health guidance, and why validation, privacy and trust will decide its future.
PMS relief is moving beyond pain pills. Bayer’s Midol campaign ties symptom care to movement, creators, and menstrual wellness.
Viatris has patch expertise. FDA scrutiny now decides whether lower estrogen and adhesion data can turn MR-100A-01 into a real growth lever.
Is Noema Pharma AG building a menopause therapy platform? Discover how cendifensine could reshape non-hormonal treatment strategies
Sun Pharma gets global scale with Organon. The harder test is whether women’s health, biosimilars, and debt discipline can move together.
Vistagen advances refisolone for menopausal hot flashes after FDA clearance. Find out what this means for non-hormonal treatment options.
Uqora has entered Target stores and Target.com. Find out what this expansion means for urinary health retail and women’s wellness growth.
AbCellera will reveal Phase 1 ABCL635 data on May 11. Read why this menopause drug update could matter for investors and women’s health watchers.